Glu-urea-Lys-(HE)3-HBED-CC-IRDye800CW (PSMA-914) was used in a proof-of-concept study, with a first, pre-operative PET/CT imaging, 1-day prior surgery in a patient with high-risk prostate carcinoma and a second PET/CT imaging, after the surgical removal of the primary tumor [140]. The gene discussed is FOLH1; the disease is prostate carcinoma.